» Articles » PMID: 34601669

Is Minimally Invasive Liver Surgery a Reasonable Option in Recurrent HCC? A Snapshot from the I Go MILS Registry

Abstract

Laparoscopic liver resection (LLR) for Hepatocellular carcinoma (HCC) is a safe procedure. Repeat surgery is more often required, and the role of minimally invasive liver surgery (MILS) is not yet clearly defined. The present study analyzes data compiled by the Italian Group of Minimally Invasive Liver Surgery (IGoMILS) on LLR. To compare repeated LLR with the first LLR for HCC is the primary endpoint. The secondary endpoint was to evaluate the outcome of repeat LLR in the case of primary open versus primary MILS surgery. The data cohort is divided into two groups. Group 1: first liver resection and Group 2: Repeat LLR. To compare the two groups a 3:1 Propensity Score Matching is performed to analyze open versus MILS primary resection. Fifty-two centers were involved in the present study, and 1054 patients were enrolled. 80 patients underwent to a repeat LLR. The type of resection was different, with more major resections in the group 1 before matching the two groups. After propensity score matching 3:1, each group consisted of 222 and 74 patients. No difference between the two groups was observed. In the subgroup analysis, in 44 patients the first resection was performed by an open approach. The other 36 patients were resected with a MILS approach. We found no difference between these two subgroups of patients. The present study in repeat MILS for HCC using the IGoMILS Registry has observed the feasibility and safety of the MILS procedure.

Citing Articles

Essential updates 2022/2023: A review of current topics in robotic hepatectomy.

Adachi T, Hara T, Matsushima H, Soyama A, Eguchi S Ann Gastroenterol Surg. 2024; 8(5):774-777.

PMID: 39229556 PMC: 11368489. DOI: 10.1002/ags3.12817.


Robotic Complete ALPPS (rALPPS)-First German Experiences.

Arend J, Franz M, Rose A, March C, Rahimli M, Perrakis A Cancers (Basel). 2024; 16(5).

PMID: 38473426 PMC: 10930461. DOI: 10.3390/cancers16051070.


Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues.

Marrone G, Leone M, Biolato M, Liguori A, Bianco G, Spoletini G Cancers (Basel). 2023; 15(23).

PMID: 38067299 PMC: 10705300. DOI: 10.3390/cancers15235593.


Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: a systematic review of propensity score-matched studies.

Hu Y, Hu H, Ma W, Jin Y, Li F Updates Surg. 2023; 75(8):2049-2061.

PMID: 37919559 PMC: 10710389. DOI: 10.1007/s13304-023-01648-8.


Ten years of Italian mini-invasiveness: the I Go MILS registry as a tool of dissemination, characterization and networking.

Ratti F, Ferrero A, Guglielmi A, Cillo U, Giuliante F, Mazzaferro V Updates Surg. 2023; 75(6):1457-1469.

PMID: 37488408 DOI: 10.1007/s13304-023-01597-2.


References
1.
Ettorre G, Levi Sandri G, Santoro R, Vennarecci G, Lepiane P, Colasanti M . Laparoscopic liver resection for hepatocellular carcinoma in cirrhotic patients: single center experience of 90 cases. Hepatobiliary Surg Nutr. 2015; 4(5):320-4. PMC: 4607835. DOI: 10.3978/j.issn.2304-3881.2015.06.13. View

2.
Lin K, Chueh K, Lu J, Chuang S, Wu B, Lee Y . Low Intensity Extracorporeal Shock Wave Therapy as a Novel Treatment for Stress Urinary Incontinence: A Randomized-Controlled Clinical Study. Medicina (Kaunas). 2021; 57(9). PMC: 8470836. DOI: 10.3390/medicina57090947. View

3.
Lu M, Chen S, Zhou Q, Wang L, Peng T, Wang G . Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): A study based on 477 patients. Medicine (Baltimore). 2019; 98(28):e16426. PMC: 6641864. DOI: 10.1097/MD.0000000000016426. View

4.
Gon H, Kido M, Tanaka M, Kuramitsu K, Komatsu S, Awazu M . Laparoscopic repeat hepatectomy is a more favorable treatment than open repeat hepatectomy for contralateral recurrent hepatocellular carcinoma cases. Surg Endosc. 2020; 35(6):2896-2906. DOI: 10.1007/s00464-020-07728-9. View

5.
Mori Y, Kataoka H, Ebi M, Adachi K, Yamaguchi Y, Hayashi N . Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer. J Gastrointest Cancer. 2021; 53(4):930-938. DOI: 10.1007/s12029-021-00711-0. View